Childhood Interstitial Lung Diseases: Lessons Learned From 15‐Year Observation at a Polish Referral Center
- 9 May 2025
- journal article
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (5) , e71112
Abstract
Background: Childhood interstitial lung diseases (chILD) are rare, chronic lung diseases characterized by symptoms such as tachypnea, dyspnea, hypoxemia, crackles, and diffuse parenchymal abnormalities on chest imaging. Objective: To evaluate the etiologic spectrum, clinical presentation, management, and outcomes of chILD at a Polish referral center. Methods: We retrospectively reviewed data from patients (0−18 years) diagnosed with chILD, admitted to the Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, from June 2009 to February 2024, classified according to the chILD‐EU categorization system. Results: A total of 275 patients (65.5% male) were included, with a median age at diagnosis of 13 months (range: 1‐221). Persistent tachypnea of infancy (PTI)/neuroendocrine cell hyperplasia of infancy (NEHI) was the most common diagnosis (52.4%), followed by disorders related to systemic diseases (11.3%) and related to exposures (10.2%). 13.8% of diseases remained undefined. The predominant symptoms included crackles (81.5%), dyspnea (72.7%) and tachypnea (68.3%). All children underwent chest computed tomography. Bronchoscopy, genetic testing, and lung biopsy were performed in 46.2%, 34.9%, and 21.4% of cases, respectively. Most children (92.7%) received some form of treatment, including inhaled bronchodilators/steroids (68.8%), systemic steroids (26.5%), long‐term macrolides (16.3%), and immunosuppressants (11.6%). Oxygen supplementation and nutritional support were required in 50.5% and 29.8% of patients, respectively. At a median follow‐up of 31.5 months, 92.9% of patients achieved clinical improvement or stabilization, and 6.2% deteriorated, including seven deaths. The 5‐year survival rate was 95.66%. Conclusion: This study highlights the significant diversity within chILD, with PTI/NEHI being the most common condition.Keywords
This publication has 29 references indexed in Scilit:
- Persistent tachypnea of infancy, neuroendocrine cell hyperplasia of infancy, and pulmonary interstitial glycogenosis: “A3‐Specific conditions of undefined etiology”Pediatric Pulmonology, 2024
- Emerging Treatments for Childhood Interstitial Lung DiseasePediatric Drugs, 2023
- Childhood interstitial lung disease in Turkey: first data from the national registryEuropean Journal of Pediatrics, 2023
- The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohortPediatric Pulmonology, 2023
- Genetic testing for diffuse lung diseases in childrenPediatric Pulmonology, 2023
- Lung biopsy in the diagnosis and management of chILDPediatric Pulmonology, 2023
- French national cohort of neuroendocrine cell hyperplasia of infancy (FRENCHI) study: diagnosis and initial managementEuropean Journal of Pediatrics, 2022
- The improved clinical course of persistent tachypnea of infancy with inhaled bronchodilators and corticosteroidsPediatric Pulmonology, 2021
- Familial neuroendocrine cell hyperplasia of infancyPediatric Pulmonology, 2010
- Idiopathic interstitial pneumonitis in children: A national survey in the United Kingdom and IrelandPediatric Pulmonology, 2002